Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Metastatic melanoma has a poor prognosis with high resistance to chemotherapy and radiation. Recently, the anti-CTLA-4 antibody ipilimumab has demonstrated clinical efficacy, being the first agent to significantly prolong the overall survival of inoperable stage III/IV melanoma patients. A major aim of patient immune monitoring is the identification of biomarkers that predict clinical outcome. We studied circulating myeloid-derived suppressor cells (MDSC) in ipilimumab-treated patients to detect alterations in the myeloid cell compartment and possible correlations with clinical outcome. Lin(-) CD14(+) HLA-DR(-) monocytic MDSC were enriched in peripheral blood of melanoma patients compared to healthy donors (HD). Tumor resection did not significantly alter MDSC frequencies. During ipilimumab treatment, MDSC frequencies did not change significantly compared to baseline levels. We observed high inter-patient differences. MDSC frequencies in ipilimumab-treated patients were independent of baseline serum lactate dehydrogenase levels but tended to increase in patients with severe metastatic disease (M1c) compared to patients with metastases in skin or lymph nodes only (M1a), who had frequencies comparable to HD. Interestingly, clinical responders to ipilimumab therapy showed significantly less lin(-) CD14(+) HLA-DR(-) cells as compared to non-responders. The data suggest that the frequency of monocytic MDSC may be used as predictive marker of response, as low frequencies identify patients more likely benefitting from ipilimumab treatment. Prospective clinical trials assessing MDSC frequencies as potential biomarkers are warranted to validate these observations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“both a low baseline frequency of MDSCs and a low frequency of MDSCs in the blood of patients with melanoma following ipilimumab treatment were associated with favorable therapy outcome (134, 169-171).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [169]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“patients with cancer who have high levels of circulating MDSCs have been found to respond poorly to checkpoint blockade”
From LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer (2018) · cites this paper as Meyer et al., 2014
Experimental — accuracy not yet measuredIn the citing paper
“lower numbers of MDSCs in melanoma patients were associated with a better response to Ipilimumab (CTLA-4 antibody) (Meyer et al., 2014).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Meyer et al., 2014
In the citing paper
“numerous studies of patients with cancer have indeed found that these myeloid cell subsets, whether in the tumor or in peripheral tissues, were negatively correlated with effective ICI therapy (134, 161, 168-171).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [169]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 5×
“However, autoimmune responses are also promoted, as 10–15 % of patients develop severe grade 3–4 immune-related adverse events [8].”
BackgroundInfluentialThe blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496 · cited 1×
“Recently, the fully humanized anti-CTLA-4 antibody ipilimumab was reported to increase overall survival of stage III/IV metastatic melanoma patients [8, 9].”
BackgroundCoordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · cited 1×
“Different malignancies favor the accumulation of different MDSC phenotypes in patients [29].”
BackgroundWolchok, J. D., Hoos, A., O'Day, S., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,222
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., Demidov, L. V., Hassel, J. C., Rutkowski, P., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,160
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156 · cited 1×
“About 50 % of melanomas express BRAF-activating mutations [4], which are V600E and V600K substitutions in 95 % of cases [5].”
Background
Cited by
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
“Reports suggest that the presence of MDSCs in the tumor microenvironment correlates with decreased efficacy of immunotherapies, including immune checkpoint therapy (Meyer et al., 2014), adoptive T cell therapy (Kodumudi et al., 2012), and DC vaccination (Laborde et al., 2014).”
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286
Bagchi, S., Yuan, R., & Engleman, E. G. (2021) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-042020-042741 · Cited by 2,189
Myeloid-Derived Suppressor Cells
Gabrilovich, D. I. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0297 · Cited by 1,882
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648
Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment
Schulte-Schrepping, J., Reusch, N., Paclik, D., Baßler, K., Schlickeiser, S., Zhang, B., Krämer, B., Krammer, T., Brumhard, S., Bonaguro, L., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.001 · Cited by 1,461
“CD14+HLA-DRlo monocytes have also been implicated with immunosuppression in cancer patients (Bronte et al., 2016;Mengos et al., 2019; Meyer et al., 2014).”
Hiam-Galvez, K. J., Allen, B. M., & Spitzer, M. H. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00347-z · Cited by 1,400
Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected
Marvel, D., & Gabrilovich, D. I. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80005 · Cited by 1,050
Pitt, J. M., Vétizou, M., Daillère, R., Roberti, M. P., Yamazaki, T., Routy, B., Lepage, P., Boneca, I. G., Chamaillard, M., Kroemer, G., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.06.001 · Cited by 1,041
Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
De Henau, O., Rausch, M., Winkler, D., Campesato, L. F., Liu, C., Cymerman, D. H., Budhu, S., Ghosh, A., Pink, M., Tchaicha, J., et al. (2016) · Nature · doi:10.1038/nature20554 · Cited by 860
Condamine, T., Dominguez, G. A., Youn, J.-I., Kossenkov, A. V., Mony, S., Alicea-Torres, K., Tcyganov, E., Hashimoto, A., Nefedova, Y., Lin, C., et al. (2016) · Science Immunology · doi:10.1126/sciimmunol.aaf8943 · Cited by 789
Genetics and biology of prostate cancer
Wang, G., Zhao, D., Spring, D. J., & DePinho, R. A. (2018) · Genes & Development · doi:10.1101/gad.315739.118 · Cited by 750
High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy
Krieg, C., Nowicka, M., Guglietta, S., Schindler, S., Hartmann, F. J., Weber, L. M., Dummer, R., Robinson, M. D., Levesque, M. P., & Becher, B. (2018) · Nature Medicine · doi:10.1038/nm.4466 · Cited by 735
Vaccines for established cancer: overcoming the challenges posed by immune evasion
van der Burg, S. H., Arens, R., Ossendorp, F., van Hall, T., & Melief, C. J. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.16 · Cited by 709
Kumar, V., Donthireddy, L., Marvel, D., Condamine, T., Wang, F., Lavilla-Alonso, S., Hashimoto, A., Vonteddu, P., Behera, R., Goins, M. A., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.10.005 · Cited by 653
Fares, C. M., Van Allen, E. M., Drake, C. G., Allison, J. P., & Hu-Lieskovan, S. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_240837 · Cited by 653
Ugel, S., De Sanctis, F., Mandruzzato, S., & Bronte, V. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80006 · Cited by 559
Martens, A., Wistuba-Hamprecht, K., Foppen, M. G., Yuan, J., Postow, M. A., Wong, P., Romano, E., Khammari, A., Dreno, B., Capone, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2412 · Cited by 541
Self-citationReck, M., Luft, A., Szczesna, A., Havel, L., Kim, S.-W., Akerley, W., Pietanza, M. C., Wu, Y.-L., Zielinski, C., Thomas, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.6601 · Cited by 538
Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors
Weber, R., Fleming, V., Hu, X., Nagibin, V., Groth, C., Altevogt, P., Utikal, J., & Umansky, V. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01310 · Cited by 538
Regulation of Tumor Metastasis by Myeloid-Derived Suppressor Cells
Condamine, T., Ramachandran, I., Youn, J.-I., & Gabrilovich, D. I. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-051013-052304 · Cited by 521
Ostrand-Rosenberg, S., & Fenselau, C. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701019 · Cited by 509
LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer
Tavazoie, M. F., Pollack, I., Tanqueco, R., Ostendorf, B. N., Reis, B. S., Gonsalves, F. C., Kurth, I., Andreu-Agullo, C., Derbyshire, M. L., Posada, J., et al. (2018) · Cell · doi:10.1016/j.cell.2017.12.026 · Cited by 476
“Consequently, patients with cancer who have high levels of circulating MDSCs have been found to respond poorly to checkpoint blockade (Meyer et al., 2014; Weber et al., 2016).”
Radiotherapy and Immunogenic Cell Death
Golden, E. B., & Apetoh, L. (2015) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2014.07.005 · Cited by 463
Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer
Law, A. M. K., Valdes-Mora, F., & Gallego-Ortega, D. (2020) · Cells · doi:10.3390/cells9030561 · Cited by 455
Chiu, D. K.-C., Tse, A. P.-W., Xu, I. M.-J., Di Cui, J., Lai, R. K.-H., Li, L. L., Koh, H.-Y., Tsang, F. H.-C., Wei, L. L., Wong, C.-M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00530-7 · Cited by 448
The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression
Umansky, V., Blattner, C., Gebhardt, C., & Utikal, J. (2016) · Vaccines · doi:10.3390/vaccines4040036 · Cited by 438
Targeted deletion of PD-1 in myeloid cells induces antitumor immunity
Strauss, L., Mahmoud, M. A. A., Weaver, J. D., Tijaro-Ovalle, N. M., Christofides, A., Wang, Q., Pal, R., Yuan, M., Asara, J., Patsoukis, N., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.aay1863 · Cited by 437
T Cell Dysfunction and Exhaustion in Cancer
Zhang, Z., Liu, S., Zhang, B., Qiao, L., Zhang, Y., & Zhang, Y. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00017 · Cited by 385
Gebhardt, C., Sevko, A., Jiang, H., Lichtenberger, R., Reith, M., Tarnanidis, K., Holland-Letz, T., Umansky, L., Beckhove, P., Sucker, A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0676 · Cited by 367
Potential roles and targeted therapy of the CXCLs/CXCR2 axis in cancer and inflammatory diseases
Cheng, Y., Ma, X.-L., Wei, Y.-Q., & Wei, X.-W. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.01.005 · Cited by 344
De Cicco, P., Ercolano, G., & Ianaro, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01680 · Cited by 332
Biomarker-guided therapy for colorectal cancer: strength in complexity
Sveen, A., Kopetz, S., & Lothe, R. A. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0241-1 · Cited by 320
PD-1/PD-L1 and immunotherapy for pancreatic cancer
Feng, M., Xiong, G., Cao, Z., Yang, G., Zheng, S., Song, X., You, L., Zheng, L., Zhang, T., & Zhao, Y. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.08.006 · Cited by 318
Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment
Ruffin, A. T., Li, H., Vujanovic, L., Zandberg, D. P., Ferris, R. L., & Bruno, T. C. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00531-9 · Cited by 305
Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies
Passaro, A., Brahmer, J., Antonia, S., Mok, T., & Peters, S. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01845 · Cited by 303
Role of the Microenvironment in Liver Metastasis: From Pre- to Prometastatic Niches
Brodt, P. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0460 · Cited by 301
Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression
Saleh, R., & Elkord, E. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.017 · Cited by 292
Single-cell RNA sequencing reveals evolution of immune landscape during glioblastoma progression
Yeo, A. T., Rawal, S., Delcuze, B., Christofides, A., Atayde, A., Strauss, L., Balaj, L., Rogers, V. A., Uhlmann, E. J., Varma, H., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01215-0 · Cited by 290
Resistance to Checkpoint Inhibition in Cancer Immunotherapy
Barrueto, L., Caminero, F., Cash, L., Makris, C., Lamichhane, P., & Deshmukh, R. R. (2020) · Translational Oncology · doi:10.1016/j.tranon.2019.12.010 · Cited by 281
Weber, J., Gibney, G., Kudchadkar, R., Yu, B., Cheng, P., Martinez, A. J., Kroeger, J., Richards, A., McCormick, L., Moberg, V., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0193 · Cited by 248
Novel technologies and emerging biomarkers for personalized cancer immunotherapy
Yuan, J., Hegde, P. S., Clynes, R., Foukas, P. G., Harari, A., Kleen, T. O., Kvistborg, P., Maccalli, C., Maecker, H. T., Page, D. B., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0107-3 · Cited by 229
Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy
Gnjatic, S., Bronte, V., Brunet, L. R., Butler, M. O., Disis, M. L., Galon, J., Hakansson, L. G., Hanks, B. A., Karanikas, V., Khleif, S. N., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0243-4 · Cited by 228
Tamura, R., Tanaka, T., Akasaki, Y., Murayama, Y., Yoshida, K., & Sasaki, H. (2020) · Medical Oncology · doi:10.1007/s12032-019-1329-2 · Cited by 226
Conniot, J., Scomparin, A., Peres, C., Yeini, E., Pozzi, S., Matos, A. I., Kleiner, R., Moura, L. I. F., Zupančič, E., Viana, A. S., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0512-0 · Cited by 219
The multifaceted immune regulation of bladder cancer
Schneider, A. K., Chevalier, M. F., & Derré, L. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0226-y · Cited by 219
Cholangiocarcinoma — novel biological insights and therapeutic strategies
Ilyas, S. I., Affo, S., Goyal, L., Lamarca, A., Sapisochin, G., Yang, J. D., & Gores, G. J. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00770-1 · Cited by 217
Innate Immunity and Cancer Pathophysiology
Maiorino, L., Daßler-Plenker, J., Sun, L., & Egeblad, M. (2022) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-032221-115501 · Cited by 215
Emerging strategies for combination checkpoint modulators in cancer immunotherapy
Popovic, A., Jaffee, E. M., & Zaidi, N. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120775 · Cited by 212
Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Dysthe, M., & Parihar, R. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-35723-8_8 · Cited by 210
Exosomes miR-126a released from MDSC induced by DOX treatment promotes lung metastasis
Deng, Z., Rong, Y., Teng, Y., Zhuang, X., Samykutty, A., Mu, J., Zhang, L., Cao, P., Yan, J., Miller, D., et al. (2017) · Oncogene · doi:10.1038/onc.2016.229 · Cited by 207
Tobin, R. P., Jordan, K. R., Robinson, W. A., Davis, D., Borges, V. F., Gonzalez, R., Lewis, K. D., & McCarter, M. D. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.08.007 · Cited by 204
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer
Cheng, W., Kang, K., Zhao, A., & Wu, Y. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01581-2 · Cited by 204
Masucci, G. V., Cesano, A., Hawtin, R., Janetzki, S., Zhang, J., Kirsch, I., Dobbin, K. K., Alvarez, J., Robbins, P. B., Selvan, S. R., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0178-1 · Cited by 202
Sade-Feldman, M., Kanterman, J., Klieger, Y., Ish-Shalom, E., Olga, M., Saragovi, A., Shtainberg, H., Lotem, M., & Baniyash, M. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3104 · Cited by 201
Cancer Vaccines, Adjuvants, and Delivery Systems
Paston, S. J., Brentville, V. A., Symonds, P., & Durrant, L. G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.627932 · Cited by 200
Alban, T. J., Alvarado, A. G., Sorensen, M. D., Bayik, D., Volovetz, J., Serbinowski, E., Mulkearns-Hubert, E. E., Sinyuk, M., Hale, J. S., Onzi, G. R., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.122264 · Cited by 197
Study and analysis of antitumor resistance mechanism of PD1/PD‐L1 immune checkpoint blocker
Wang, Z., & Wu, X. (2020) · Cancer Medicine · doi:10.1002/cam4.3410 · Cited by 195
Predictive biomarkers of response for immune checkpoint inhibitors in non–small-cell lung cancer
Prelaj, A., Tay, R., Ferrara, R., Chaput, N., Besse, B., & Califano, R. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.11.002 · Cited by 193
Resistance mechanisms to immune checkpoint inhibitors: updated insights
Alsaafeen, B. H., Ali, B. R., & Elkord, E. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02212-7 · Cited by 191
Immune checkpoint inhibitors: a promising anticancer therapy
Singh, S., Hassan, D., Aldawsari, H. M., Molugulu, N., Shukla, R., & Kesharwani, P. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2019.11.003 · Cited by 189
Dominguez, G. A., Condamine, T., Mony, S., Hashimoto, A., Wang, F., Liu, Q., Forero, A., Bendell, J., Witt, R., Hockstein, N., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1784 · Cited by 187
Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system
Pico de Coaña, Y., Choudhury, A., & Kiessling, R. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.05.005 · Cited by 184
Bispecific antibody based therapeutics: Strengths and challenges
Thakur, A., Huang, M., & Lum, L. G. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.02.004 · Cited by 183
Martens, A., Wistuba-Hamprecht, K., Yuan, J., Postow, M. A., Wong, P., Capone, M., Madonna, G., Khammari, A., Schilling, B., Sucker, A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0249 · Cited by 180
The tumor microenvironment’s role in the response to immune checkpoint blockade
Aliazis, K., Christofides, A., Shah, R., Yeo, Y. Y., Jiang, S., Charest, A., & Boussiotis, V. A. (2025) · Nature Cancer · doi:10.1038/s43018-025-00986-3 · Cited by 178
Myeloid-Derived Suppressor Cells: A Propitious Road to Clinic
Grover, A., Sanseviero, E., Timosenko, E., & Gabrilovich, D. I. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0764 · Cited by 175
Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses
Oliver, A. J., Lau, P. K. H., Unsworth, A. S., Loi, S., Darcy, P. K., Kershaw, M. H., & Slaney, C. Y. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00070 · Cited by 169
Gandhi, S., Pandey, M. R., Attwood, K., Ji, W., Witkiewicz, A. K., Knudsen, E. S., Allen, C., Tario, J. D., Wallace, P. K., Cedeno, C. D., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2381 · Cited by 165
Biomarkers for Immunotherapy: Current Developments and Challenges
Spencer, K. R., Wang, J., Silk, A. W., Ganesan, S., Kaufman, H. L., & Mehnert, J. M. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_160766 · Cited by 162
Combining epigenetic and immune therapy to overcome cancer resistance
Gomez, S., Tabernacki, T., Kobyra, J., Roberts, P., & Chiappinelli, K. B. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.019 · Cited by 160
Mengos, A. E., Gastineau, D. A., & Gustafson, M. P. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01147 · Cited by 160
Myeloid cell heterogeneity in cancer: not a single cell alike
Kiss, M., Van Gassen, S., Movahedi, K., Saeys, Y., & Laoui, D. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.02.008 · Cited by 159
Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
Bai, J., Gao, Z., Li, X., Dong, L., Han, W., & Nie, J. (2017) · Oncotarget · doi:10.18632/oncotarget.22690 · Cited by 158
Nixon, A. B., Schalper, K. A., Jacobs, I., Potluri, S., Wang, I.-M., & Fleener, C. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0799-2 · Cited by 154
Turn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression
Awad, R. M., De Vlaeminck, Y., Maebe, J., Goyvaerts, C., & Breckpot, K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01977 · Cited by 151
Beyond the Barrier: Unraveling the Mechanisms of Immunotherapy Resistance
Bell, H. N., & Zou, W. (2024) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101819-024752 · Cited by 149
The diverse roles of the TNF axis in cancer progression and metastasis.
Ham, B., Fernández, M. C., D'Costa, Z., & Brodt, P. (2016) · PubMed · Cited by 149
Systemic Reprogramming of Monocytes in Cancer
Kiss, M., Caro, A. A., Raes, G., & Laoui, D. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01399 · Cited by 147
Zhou, X., Ni, Y., Liang, X., Lin, Y., An, B., He, X., & Zhao, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.915094 · Cited by 145
Hou, A., Hou, K., Huang, Q., Lei, Y., & Chen, W. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00783 · Cited by 145
Holtzhausen, A., Harris, W. P., Ubil, E., Hunter, D. M., Zhao, J., Zhang, Y., Zhang, D., Liu, Q., Wang, X., Graham, D. K., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0008 · Cited by 145
Wang, P.-F., Song, S., Wang, T., Ji, W., Li, S., Liu, N., & Yan, C. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1494113 · Cited by 144
Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives
Krasniqi, E., Barchiesi, G., Pizzuti, L., Mazzotta, M., Venuti, A., Maugeri‐Saccà, M., Sanguineti, G., Massimiani, G., Sergi, D., Carpano, S., et al. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0798-2 · Cited by 143
Myeloid-Derived Cells in Tumors: Effects of Radiation
Vatner, R. E., & Formenti, S. C. (2014) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2014.07.008 · Cited by 142
de Coaña, Y. P., Wolodarski, M., Poschke, I., Yoshimoto, Y., Yang, Y., Nyström, M., Edbäck, U., Brage, S. E., Lundqvist, A., Masucci, G. V., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15368 · Cited by 139
IL-6 regulates CCR5 expression and immunosuppressive capacity of MDSC in murine melanoma
Weber, R., Riester, Z., Hüser, L., Sticht, C., Siebenmorgen, A., Groth, C., Hu, X., Altevogt, P., Utikal, J. S., & Umansky, V. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000949 · Cited by 139
The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy
Wang, X., Wang, F., Zhong, M., Yarden, Y., & Fu, L. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01200-x · Cited by 139
Tengesdal, I. W., Dinarello, A., Powers, N. E., Burchill, M. A., Joosten, L. A. B., Marchetti, C., & Dinarello, C. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.661323 · Cited by 138
Liu, Y., Sun, Y., Wang, P., Li, S., Dong, Y., Zhou, M., Shi, B., Jiang, H., Sun, R., & Li, Z. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04080-z · Cited by 137
Inhibition of estrogen signaling in myeloid cells increases tumor immunity in melanoma
Chakraborty, B., Byemerwa, J. K., Shepherd, J., Haines, C., Baldi, R., Gong, W., Liu, W., Mukherjee, D., Artham, S., Lim, F., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci151347 · Cited by 137
Overcoming cold tumors: a combination strategy of immune checkpoint inhibitors
Ouyang, P., Wang, L., Wu, J., Tian, Y., Chen, C., Li, D., Yao, Z., Chen, R., Xiang, G., Gong, J., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1344272 · Cited by 137
Targeting inflammation as cancer therapy
Wang, M., Chen, S., He, X., Yuan, Y., & Wei, X. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01528-7 · Cited by 136
PI3K activation allows immune evasion by promoting an inhibitory myeloid tumor microenvironment
Collins, N. B., Abosy, R. A., Miller, B. C., Bi, K., Zhao, Q., Quigley, M. M., Ishizuka, J. J., Yates, K. B., Pope, H. W., Manguso, R. T., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003402 · Cited by 135
Predictive biomarkers for response to immune checkpoint inhibition
Shum, B., Larkin, J., & Turajlic, S. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.036 · Cited by 134
Kitano, S., Postow, M. A., Ziegler, C. G. K., Kuk, D., Panageas, K. S., Cortez, C., Rasalan, T., Adamow, M., Yuan, J., Wong, P., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0013 · Cited by 134
Targeting myeloid-derived suppressor cells in tumor immunotherapy: Current, future and beyond
Zhao, Y., Du, J., & Shen, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1157537 · Cited by 131
Mechanisms of Resistance to Immune Checkpoint Blockade
Liu, D., Jenkins, R. W., & Sullivan, R. J. (2019) · American Journal of Clinical Dermatology · doi:10.1007/s40257-018-0389-y · Cited by 130
Nosrati, A., Tsai, K. K., Goldinger, S. M., Tumeh, P., Grimes, B., Loo, K., Algazi, A. P., Nguyen-Kim, T. D. L., Levesque, M., Dummer, R., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.70 · Cited by 127
Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy
Vanderstraeten, A., Luyten, C., Verbist, G., Tuyaerts, S., & Amant, F. (2014) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-014-1537-8 · Cited by 126
Metadata
- Authors
- Meyer, C., Cagnon, L., Costa-Nunes, C. M., Baumgaertner, P., Montandon, N., Leyvraz, L., Michielin, O., Romano, E., & Speiser, D. E.
- Affiliations
- University of Lausanne (CH)
- Centre Hospitalier Universitaire Vaudois (CH)
- Corresponding author
- Speiser, Daniel E.
- Venue
- Cancer Immunology Immunotherapy
- Published
- 2013-12-20
- Volume
- 63
- Issue
- 3
- Pages
- 247-257
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- PMC
- PMC11029062
- OpenAlex
- W2080886891
- Cited by
- 560
- References
- 58
- Citations by year
- 2026: 12 · 2025: 37 · 2024: 29 · 2023: 59 · 2022: 64 · 2021: 73 · 2020: 85 · 2019: 49 · 2018: 36 · 2017: 36 · 2016: 33 · 2015: 25 · 2014: 18 · 2013: 1
- FWCI
- 14.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Cancer Immunology Immunotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- SERVAL (Université de Lausanne) (publishedVersion, other-oa)
- Archive ouverte UNIGE (University of Geneva) (publishedVersion, other-oa)
- reroDoc Digital Library (submittedVersion)
- IRIS (submittedVersion)
- Funders
- National Science Foundation
- Ludwig Institute for Cancer Research
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (141879, 135553, 310030)
- Fondation ISREC
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- myeloid-derived suppressor cells, metastatic melanoma, ipilimumab, CTLA-4 blockade, predictive biomarkers, treatment response, monocytic MDSCs, tumor resection, lactate dehydrogenase, immune monitoring
- MeSH terms
- Ipilimumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Cell Count, Female, Humans, Immune Tolerance, Male, Melanoma, Middle Aged, Neoplasm Metastasis, Neoplasm Staging, Skin Neoplasms, Treatment Outcome, Lipopolysaccharide Receptors, Myeloid Cells, Biomarkers, Pharmacological, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.